Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules

European Journal of Clinical Investigation

Volumn 29, Issue 11, 1999, Pages 913-921

  Van Baal, W M ^a,c   Emeis, J J ^b   Kenemans, P ^a,c   Kessel, H ^a,c   Peters Muller, E R A ^a,c   Schalkwijk, C G ^a   Van Der Mooren, M J ^a,c   Stehouwer, C D A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adhesion molecules; Cardiovascular risk; Endothelial function; Flow mediated vasodilatation; Hormone replacement therapy; Oestrogens

Indexed keywords

CELL ADHESION MOLECULE; DYDROGESTERONE; DYDROGESTERONE PLUS ESTRADIOL; ENDOTHELIN 1; ESTRADIOL; GESTAGEN; INTERCELLULAR ADHESION MOLECULE 1; TRIMEGESTONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

CHOLESTEROL; E-SELECTIN; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MIDDLE AGED; NITROGLYCERIN; PLACEBOS; POSTMENOPAUSE; PROGESTINS; PROMEGESTONE; PROSPECTIVE STUDIES; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION;

EID: 0032739824     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00565.x     Document Type: Article

References (46)

1. 1 Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
2. 2 Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
3. 3 Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
4. 4 Ridker PM. Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic disease - hotline editorial. Eur Heart J 1998; 19: 1119-21.
5. 5 Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-34.
6. 6 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
7. 7 Stehouwer CDA, Lambert J, Donker AJM, Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
8. 8 Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
9. 9 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
10. 10 Badimon L, Badimon JJ, Chesebro JH, Fuster V. Von Willebrandt factor and cardiovascular disease. Thromb Haemostas 1993; 70: 111-8.
11. 11 Omland O, Terje R, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
12. 12 Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 59: 115-20.
13. 13 Blann AD, Miller JP, McCollum CN. Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997; 132: 151-6.
14. 14 Lieberman EH, Gerhard MD, Uehata A et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121: 936-41.
15. 15 Wilcox JG, Hatch IE, Gentzschein E, Stanczyk FZ, Lobo RA. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril 1997; 67: 273-7.
16. 16 Ciceneli E, Ignarro LJ, Lograno M, Matteo G, Falco N, Schonauer LM. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril 1997; 68: 63-6.
17. 17 Pinto S, Virdis A, Ghiadoni L et al. Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Hypertension 1997; 29: 268-73.
18. 18 Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-32.
19. 19 McCrohon JA, Adams MR, McCredie RJ et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol 1996; 45: 435-41.
20. 20 Ylikorkala O, Cacciatore B, Paakkari I et al. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998; 69: 883-8.
21. 21 Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension 1995; 25: 848-53.
22. 22 Sorensen KE, Dorup I, Hermann AP et al. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998; 97: 1234-8.
23. 23 Chen FP, Lee N, Wang CH et al. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998; 69: 267-73.
24. 24 Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17-beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 1997; 82: 388-94.
25. 25 Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17b-oestradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98: 36-42.
26. 26 Caulin-Glaser T, Farrell WJ, Pfau SE et al. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. JACC 1998; 31: 1555-60.
27. 27 Ingerslev JA. A sensitive ELISA for von Willebrand factor (vWF. Ag) Scand J Clin Lab Invest 1957; 17: 237-46.
28. 28 Lambert J, 'Aarsen M, Donker AJM, Stehouwer CDA. Endothelium-dependent and -independent vasodilatation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 705-11.
29. 29 Thomas CG, van den Berg RJ, Seger MFG, Bartelink ML, Thien T. Inaccurate measurements of 17b-oestradiol in serum of female volunteers after oral administration of milligram amounts of micronised 17b-oestradiol. Clin Chem 1993; 39: 2341-2.
30. 30 Yudkin PL, Stratton IM. How to deal with regression to the mean in intervention studies. Lancet 1996; 347: 241-3.
31. 31 Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Bioph Res Comm 1992; 187: 584-9.
32. 32 Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases - the atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 4219-42.
33. 33 Jilma B, Eichler HG, Breiteneder H et al. Effects of 17 beta-estradiol on circulating adhesion molecules. J Clin Endocrinol Metab 1994; 79: 1619-24.
34. 34 Jassoni VM, Buemi M, D'Anna R et al. Lack of endogenous estrogen effects on circulation molecule ICAM-1. J Endocrinol Invest 1997; 20: 621-2.
35. 35 Van Baal WM, Kenemans P, Emeis JJ et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71: 663-70.
36. 36 Sadler JE. Thrombomodulin structure and function. Thromb Haemostas 1997; 78: 392-5.
37. 37 Blann AD, Daly RJ, Amiral J. The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Br J Haematol 1996; 92: 498-500.
38. 38 Nilsson TK, Hellsten G, Admiral J. Plasma thrombomodulin concentration in relation to cardiovascular risk factors in a population sample. Blood Coag Fibrinol 1993; 4: 455-8.
39. 39 Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
40. 40 Anderson TJ, Uehata A, Gerhard MD et al. Close relationship of endothelial function in human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
41. 41 Webb D. Physiological role of endothelin system in human cardiovascular and renal haemodynamics. Curr Opin Nephrol Hypertens 1997; 6: 69-73.
42. 42 Ylikorkala O, Orpana A, Puolakka J, Pyorala T, Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab 1995; 80: 3384-7.
43. 43 Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995; 99: 119-22.
44. 44 Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786-91.
45. 45 Gerhard M, Walsh BW, Tawakol A et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998; 98: 1158-63.
46. 46 Salomaa VV, Matei C, Aleksic N et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) study: a case-cohort study. Lancet 1999; 353: 1729-34.